CN102470178A - 托伐普坦固体分散体及其制备方法 - Google Patents

托伐普坦固体分散体及其制备方法 Download PDF

Info

Publication number
CN102470178A
CN102470178A CN2011800032986A CN201180003298A CN102470178A CN 102470178 A CN102470178 A CN 102470178A CN 2011800032986 A CN2011800032986 A CN 2011800032986A CN 201180003298 A CN201180003298 A CN 201180003298A CN 102470178 A CN102470178 A CN 102470178A
Authority
CN
China
Prior art keywords
protective embankment
solid dispersions
ketone
tolvaptan
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN2011800032986A
Other languages
English (en)
Other versions
CN102470178B (zh
Inventor
吴玉霞
毛姝君
陈昊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Priority to CN2011800032986A priority Critical patent/CN102470178B/zh
Publication of CN102470178A publication Critical patent/CN102470178A/zh
Application granted granted Critical
Publication of CN102470178B publication Critical patent/CN102470178B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Dispersion Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

一种托伐普坦固体分散体及其制备方法，所述固体分散体包含托伐普坦和交联聚乙烯吡咯烷酮，重量比为1∶0.05-20，优选为1∶0.1-10，更优选2∶1。该固体分散体还可含有水溶性聚合物，例如聚乙烯吡咯烷酮、羟丙基纤维素、羟乙基纤维素或甲基纤维素，其中托伐普坦∶交联聚乙烯吡咯烷酮∶水溶性聚合物的重量比优选为2∶1∶0.1。该固体分散体具有好的热力学稳定性和溶解性，其制成的药物组合物具有提高的释放速率和生物利用度。

Description

PCT国内申请，说明书已公开。

Claims (1)

  1. PCT国内申请，权利要求书已公开。
CN2011800032986A 2010-06-25 2011-06-02 托伐普坦固体分散体及其制备方法 Expired - Fee Related CN102470178B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2011800032986A CN102470178B (zh) 2010-06-25 2011-06-02 托伐普坦固体分散体及其制备方法

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201010224884.0 2010-06-25
CN2010102248840A CN102293734A (zh) 2010-06-25 2010-06-25 托伐普坦固体分散体及其制备方法
CN2011800032986A CN102470178B (zh) 2010-06-25 2011-06-02 托伐普坦固体分散体及其制备方法
PCT/CN2011/075131 WO2011160541A1 (zh) 2010-06-25 2011-06-02 托伐普坦固体分散体及其制备方法

Publications (2)

Publication Number Publication Date
CN102470178A true CN102470178A (zh) 2012-05-23
CN102470178B CN102470178B (zh) 2013-06-05

Family

ID=45354575

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2010102248840A Pending CN102293734A (zh) 2010-06-25 2010-06-25 托伐普坦固体分散体及其制备方法
CN2011800032986A Expired - Fee Related CN102470178B (zh) 2010-06-25 2011-06-02 托伐普坦固体分散体及其制备方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN2010102248840A Pending CN102293734A (zh) 2010-06-25 2010-06-25 托伐普坦固体分散体及其制备方法

Country Status (12)

Country Link
US (1) US9408915B2 (zh)
EP (1) EP2586464B1 (zh)
JP (1) JP5991968B2 (zh)
KR (1) KR101815722B1 (zh)
CN (2) CN102293734A (zh)
AU (1) AU2011269506B2 (zh)
BR (1) BR112012031882A2 (zh)
CA (1) CA2801098C (zh)
HK (1) HK1166005A1 (zh)
MX (1) MX2012014251A (zh)
RU (1) RU2579745C2 (zh)
WO (1) WO2011160541A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112972394A (zh) * 2021-04-16 2021-06-18 浙江工业大学 一种姜黄素固体分散体及其机械力制备方法

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102793706B (zh) * 2012-08-14 2018-02-06 浙江华海药业股份有限公司 托伐普坦固体分散体的制备方法
TWI660748B (zh) * 2013-03-01 2019-06-01 日商大塚製藥股份有限公司 用於口服投藥之包含非晶型托伐普坦（Ｔｏｌｖａｐｔａｎ）的懸浮液
JP6353061B2 (ja) * 2013-09-25 2018-07-04 ダウ グローバル テクノロジーズ エルエルシー 有機液体希釈剤及び特定のヒドロキシアルキルメチルセルロースを含む組成物
RU2017135502A (ru) * 2015-03-12 2019-04-12 Геркулес Ллк Композиция для обработки нефтегазовых скважин, включающая гидроксиэтилцеллюлозу и сшитый поливинилпирролидон
JP2018024628A (ja) * 2016-08-02 2018-02-15 ニプロ株式会社 トルバプタンを含む非晶質固体分散体およびその製造方法
JP6838446B2 (ja) * 2017-03-22 2021-03-03 ニプロ株式会社 トルバプタン製剤およびその製造方法
WO2020122670A1 (ko) * 2018-12-14 2020-06-18 명인제약주식회사 톨밥탄을 포함하는 고체분산체 제조를 위한 약제학적 조성물 및 이의 제조방법
CN111888335A (zh) * 2020-08-21 2020-11-06 福安药业集团重庆礼邦药物开发有限公司 一种托伐普坦的药物固体制剂及制备方法
CN113171344B (zh) * 2021-04-12 2023-01-31 南京海纳医药科技股份有限公司 一种托伐普坦口服制剂及其制备方法
KR20230133029A (ko) 2022-03-10 2023-09-19 건양대학교산학협력단 톨밥탄을 포함하는 자가 유화 약물 전달 시스템 조성물 및 이의 제조방법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1121241A (ja) * 1997-07-03 1999-01-26 Otsuka Pharmaceut Co Ltd 固形製剤組成物
CN101686941A (zh) * 2007-06-21 2010-03-31 大塚制药株式会社 包含苯并氮杂的药物固体制剂及其生产方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2167649C2 (ru) * 1995-08-11 2001-05-27 Ниссан Кемикал Индастриз, Лтд. Способ получения твердой дисперсии умеренно водорастворимого лекарственного вещества (варианты) и фармацевтическая композиция
JP2001335483A (ja) * 2000-05-30 2001-12-04 Nichiko Pharmaceutical Co Ltd ニルバジピン含有製剤
ITMI20022748A1 (it) * 2002-12-23 2004-06-24 Eurand Int Dispersioni solide stabilizzate di farmaco in un carrier organico e procedimento per la loro preparazione.
US20040225018A1 (en) * 2003-03-17 2004-11-11 Japan Tobacco Inc. Pharmaceutical compositions of CETP inhibitors
WO2005103693A2 (en) * 2004-04-27 2005-11-03 Galapagos N.V. Methods, compositions and compound assays for inhibiting amyloid-beta protein production
GB0428152D0 (en) * 2004-12-22 2005-01-26 Novartis Ag Organic compounds
KR20140107691A (ko) * 2006-03-20 2014-09-04 버텍스 파마슈티칼스 인코포레이티드 의약 조성물
US8613946B2 (en) * 2006-12-21 2013-12-24 Isp Investment Inc. Carotenoids of enhanced bioavailability
US20080221047A1 (en) * 2006-12-27 2008-09-11 Astellas Pharma Inc., Aminoakyl methacrylate copolymer E for maintaining solubility of poorly-soluble drug
JP4879351B2 (ja) * 2007-10-19 2012-02-22 大塚製薬株式会社 医薬固形製剤

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1121241A (ja) * 1997-07-03 1999-01-26 Otsuka Pharmaceut Co Ltd 固形製剤組成物
CN101686941A (zh) * 2007-06-21 2010-03-31 大塚制药株式会社 包含苯并氮杂的药物固体制剂及其生产方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112972394A (zh) * 2021-04-16 2021-06-18 浙江工业大学 一种姜黄素固体分散体及其机械力制备方法

Also Published As

Publication number Publication date
KR20130094281A (ko) 2013-08-23
AU2011269506A1 (en) 2013-01-10
EP2586464B1 (en) 2018-07-25
JP2013530189A (ja) 2013-07-25
MX2012014251A (es) 2013-01-18
US20130102588A1 (en) 2013-04-25
CA2801098C (en) 2018-10-30
HK1166005A1 (en) 2012-10-19
EP2586464A4 (en) 2014-11-26
BR112012031882A2 (pt) 2016-11-08
WO2011160541A1 (zh) 2011-12-29
CN102470178B (zh) 2013-06-05
KR101815722B1 (ko) 2018-01-30
US9408915B2 (en) 2016-08-09
CN102293734A (zh) 2011-12-28
RU2012157685A (ru) 2014-07-27
RU2579745C2 (ru) 2016-04-10
AU2011269506B2 (en) 2015-04-09
CA2801098A1 (en) 2011-12-29
EP2586464A1 (en) 2013-05-01
JP5991968B2 (ja) 2016-09-14

Similar Documents

Publication Publication Date Title
CN102470178A (zh) 托伐普坦固体分散体及其制备方法
EP2167046B1 (en) Pharmaceutical solid preparation comprising benzazepines and production method thereof
CN102811718A (zh) 提高普拉格雷溶出度的药物组合物及其制备方法
CN104434805B (zh) 一种替格瑞洛固体分散体及其制备方法
KR20170038021A (ko) 직접 압축성 폴리비닐 알코올
JP5910949B2 (ja) 製剤用崩壊型核粒子
CN102114001A (zh) 一种含有托伐普坦的口服固体制剂
CN103007286A (zh) 一种托伐普坦的固体药物组合物
CN102274162A (zh) 一种含有难溶性药物和亲水凝胶材料的固体组合物及其制备方法
CN102614185A (zh) 缬沙坦和氢氯噻嗪的组合物及其制备方法
CN102038642A (zh) 一种银杏内酯b固体分散体及其制备方法
CN103768068A (zh) 一种波生坦药物组合物
CN111557924B (zh) 一种奥美沙坦酯氢氯噻嗪片的制备方法及奥美沙坦酯氢氯噻嗪片
CN101199540B (zh) 一种虎杖苷片剂及其制备方法
CN103054862B (zh) 一种含有马来酸氨氯地平的快速释放的口服固体制剂
CN105982904B (zh) 一种螺内酯的药物微丸组合物
CN104800185B (zh) 阿法骨化醇缓释片及其制备方法
JP6002869B1 (ja) ジエノゲスト含有錠剤
TWI523842B (zh) 托伐普坦固體分散體及其製備方法
CN105434385B (zh) 美索舒利缓释片及其制备方法
CN104784122A (zh) 一种包含苯丙哌林的固体制剂
CN107281154A (zh) 抗血栓及预防中风的Tecarfarin药物制剂及其制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1166005

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1166005

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130605